Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
NCT05905328
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Cytokine Release Syndrome
Interventions
DRUG:
CTO1681 10 μg
DRUG:
CTO1681 20 μg
DRUG:
CTO1681 30 μg
Sponsor
CytoAgents, Inc.